Schizophrenia and Psychosis

A meta-analysis of known risk factors for psychosis finds elevated risk with the presence of childhood trauma, adverse life events, and affective dysfunction.

In a commentary piece, Ben Alderson-Day and Nev Jones discuss the AVATAR therapy research for psychosis and propose further questions.

Stimulant medications like Ritalin and Adderall, often prescribed to treat children diagnosed with ADHD, are known to cause hallucinations and psychotic symptoms. Until recently these adverse effects were considered to be rare. A new study to be published in the January issue of Pediatrics challenges this belief, however, and finds that many more children may be experiencing psychotic symptoms as a result of these drugs than previously acknowledged.

The first time I heard someone labeled schizophrenic I was about 10 years old. A man was talking to himself and appeared to be house-less and perhaps on drugs. My mom, a very good teacher and explainer of things to me, said, “That man is schizophrenic. That means he can't tell the difference between what's inside of himself and what's outside.” In retrospect this seems like a relatively sophisticated and sensitive explanation; Falling in love, hearing music that enters our heart, having children/giving birth, connecting powerfully with another person in a meeting of the minds, feeling empathy, deeply caring about something, experiencing oneness with nature, are all examples of times when the line between inner and outer reality is blurred.

The authors outline reasons for renaming schizophrenia and the way a change can reform practice.

Ever since critics began asking questions about the death of Dan Markinson in a clinical trial at the University of Minnesota, the General Counsel for the university, Mark Rotenberg, has responded with a uniform message: the case has already been investigated many times, and no wrongdoing has ever been found. That's how Rotenberg responded to my article about the case in Mother Jones, and that's how he responded last week to the news that the Board of Social Work had issued a “corrective action” to the study coordinator for the clinical trial in which Markingson died.

A pathbreaking new study out of Finland suggests that early intervention programs for youth experiencing psychotic-like symptoms may see the greatest improvement when treatment works within the home rather than in a hospital setting. The research, to be published in next month’s issue of Psychiatry Research, found greater improvement in functioning, depression, and hopelessness among teens in a new need-adapted Family and Community oriented Integrative Treatment Model (FCTM) program.

Results of a large government-funded study call into question current drug heavy approaches to treating people diagnosed with schizophrenia. The study, which the New York Times called “by far the most rigorous trial to date conducted in the United States,” found that patients who received smaller doses of antipsychotic drugs with individual talk therapy, family training, and support for employment and education had a greater reduction in symptoms as well as increases in quality of life, and participation in work and school than those receiving the current standard of care.

Researchers examine the relationship between vitamin D and clinical and cognitive symptoms in first-episode psychosis.

Higher levels of sedentary behavior are associated with poorer cognitive functioning in patients diagnosed with schizophrenia.

A large review and meta-analysis of 167 studies across 60 years dissects placebo-controlled randomized controlled trials of antipsychotic drugs.

Influential psychiatrists recently called on the NHS to make a faux schizophrenia test available to patients and their families. What is most astounding about this is the complete lack of pretense. "We are so certain of our power and righteousness that we are going to tell you to your face that we are lying, and yet, we will still get our way."

Dear Senator Deeds: Hello from another fellow Virginian. First, I want to extend my deepest condolences for the horrific tragedy that befell your family last year, and for the loss of your precious son Gus. I think I know, at least in part, how agonizing it is when our loved ones cannot access helpful supports, and how it feels to watch in horror as they spiral downward into darkness and despair. We all agree that our mental health systems are broken. Those of us who have been down the hellish road of struggling with our mental health and have found recovery have developed a new vision that will take us forwards, not backwards. Please give us the opportunity to share that new vision with you.

In a featured article for Psychiatric Services, psychiatrists from Dartmouth raise the alarm on the increasing numbers of children prescribed dangerous antipsychotic drugs. Despite the fact that data on the safety of long-term use of these drugs in this vulnerable population “do not exist,” the rate of children and adolescents being prescribed antipsychotic drugs have continued to increase over the past fifteen years.

A review of mental health anti-stigma campaigns finds psychosocial models are effective in reducing stigma, while biogenetic models often worsen attitudes.

Researchers investigate the first-person experiences of people who disagreed with their psychiatric diagnosis of psychosis.

A new study in press in the Journal of Schizophrenia Research finds that patients who actively resist the negative stigma associated with mental health...

People who reduced antipsychotic use by tapering were doing just as well after five years as those who continued using the drugs.

Study finds frequency of social interactions predicts long-term remission in first-episode psychosis.

Psychiatrist outlines varying roles in Open Dialogue model, fostering service-user and family agency through meaningful conversations with a team of providers.

Common second-generation antipsychotic medications are causing symptoms of obsessive-compulsive disorder to emerge in many people who previously only had schizophrenia symptoms, according to a...

Last week, the headlines blared: "Schizophrenia breakthrough as genetic study reveals link to brain changes!"  We heard that our best hope for treating “schizophrenia” is to understand it at a genetic level, and that this new breakthrough would get us really started on that mission, as it showed how a genetic variation could lead to the more intense pruning of brain connections, which is often seen in those diagnosed with schizophrenia.  “For the first time, the origin of schizophrenia is no longer a complete black box,” said one (while admitting that "it's still early days").  The acting director of the National Institute of Mental Health (NIMH) described the study as “a crucial turning point in the fight against mental illness.” But is all this hype justified?

There is a lack of consensus in the definition of ‘relapse’ across randomized controlled trials of antipsychotic maintenance treatment for schizophrenia and psychosis.

At the University of Minnesota, the answer is apparently $1,446. If harmless clerical errors were to blame for oddities like this, that fact should be easy to clarify simply by looking at the relevant documents.  But if there are systematic issues with the administration of clinical trials that makes it possible to bill for a visit with a dead subject, those issues would be important for other universities and private trial sites as well. 

Individuals who experience psychosis can also experience posttraumatic growth, which can be a central component of the recovery paradigm.